Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.
Nat Commun
; 15(1): 4448, 2024 May 24.
Article
em En
| MEDLINE
| ID: mdl-38789460
ABSTRACT
Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC). Immune checkpoint inhibition (ICI) alone, and ICI in combination with chemotherapy, have demonstrated promising pathologic response (
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Bexiga Urinária
/
Terapia Neoadjuvante
/
Desoxicitidina
/
Gencitabina
/
Imunoterapia
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Nat Commun
Assunto da revista:
BIOLOGIA
/
CIENCIA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos